## Nancy Diazgranados

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944345/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Archives of General Psychiatry, 2010, 67, 793.	12.3	848
2	Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial. Biological Psychiatry, 2012, 71, 939-946.	1.3	695
3	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nature Neuroscience, 2018, 21, 1656-1669.	14.8	490
4	Rapid Resolution of Suicidal Ideation After a Single Infusion of an <i>N</i> -Methyl- <scp>D</scp> -Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 1605-1611.	2.2	487
5	International Society for Bipolar Disorders Task Force on Suicide: metaâ€analyses and metaâ€regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disorders, 2015, 17, 1-16.	1.9	265
6	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. Neuropsychopharmacology, 2012, 37, 1526-1533.	5.4	262
7	Ketamine and the next generation of antidepressants with a rapid onset of action. , 2009, 123, 143-150.		229
8	Glutamatergic Modulators: The Future of Treating Mood Disorders?. Harvard Review of Psychiatry, 2010, 18, 293-303.	2.1	203
9	A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry,the, 2020, 7, 1032-1045.	7.4	200
10	Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine. Neuropsychopharmacology, 2010, 35, 1415-1422.	5.4	195
11	A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2012, 32, 551-557.	1.4	187
12	Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1155-1159.	4.8	165
13	Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. Biological Psychiatry, 2013, 73, 1213-1221.	1.3	139
14	Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to an <i>N</i> -Methyl- <scp>D</scp> -Aspartate Antagonist. Journal of Clinical Psychiatry, 2009, 70, 1662-1666.	2.2	131
15	Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 785-802.	2.3	122
16	Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders. Current Pharmaceutical Design, 2009, 15, 1595-1611.	1.9	107
17	Neurofunctional Domains Derived From Deep Behavioral Phenotyping in Alcohol Use Disorder. American Journal of Psychiatry, 2019, 176, 744-753.	7.2	91
18	A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 2015, 49, 1006-1020.	2.3	87

NANCY DIAZGRANADOS

#	Article	IF	CITATIONS
19	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disorders, 2014, 16, 119-128.	1.9	74
20	Influence of alcoholism and cholesterol on TSPO binding in brain: PET [11C]PBR28 studies in humans and rodents. Neuropsychopharmacology, 2018, 43, 1832-1839.	5.4	57
21	Resting state connectivity best predicts alcohol use severity in moderate to heavy alcohol users. Neurolmage: Clinical, 2019, 22, 101782.	2.7	51
22	New Therapeutic Targets for Mood Disorders. Scientific World Journal, The, 2010, 10, 713-726.	2.1	50
23	A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Current Psychiatry Reports, 2008, 10, 510-519.	4.5	46
24	Neural Correlates of Compulsive Alcohol Seeking in Heavy Drinkers. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 1022-1031.	1.5	45
25	Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents. Science Advances, 2021, 7, .	10.3	41
26	Longitudinal gut microbiome changes in alcohol use disorder are influenced by abstinence and drinking quantity. Gut Microbes, 2020, 11, 1608-1631.	9.8	36
27	Shared genetic risk between eating disorder―and substanceâ€useâ€related phenotypes: Evidence from genomeâ€wide association studies. Addiction Biology, 2021, 26, e12880.	2.6	28
28	Striatal Dopamine Release in Response to Morphine: A [11C]Raclopride Positron Emission Tomography Study in Healthy Men. Biological Psychiatry, 2019, 86, 356-364.	1.3	20
29	Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study. Interactive Journal of Medical Research, 2022, 11, e29880.	1.4	16
30	Alcohol effects on globus pallidus connectivity: Role of impulsivity and binge drinking. PLoS ONE, 2020, 15, e0224906.	2.5	15
31	Risk Locus Identification Ties Alcohol Withdrawal Symptoms to <i><scp>SORCS</scp>2</i> . Alcoholism: Clinical and Experimental Research, 2018, 42, 2337-2348.	2.4	14
32	PPARÎ <sup>3</sup> activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study. Psychopharmacology, 2020, 237, 2367-2380.	3.1	14
33	Addiction neurocircuitry and negative affect: A role for neuroticism in understanding amygdala connectivity and alcohol use disorder. Neuroscience Letters, 2020, 722, 134773.	2.1	12
34	<i>TSPO</i> polymorphism in individuals with alcohol use disorder: Association with cholesterol levels and withdrawal severity. Addiction Biology, 2021, 26, e12838.	2.6	9
35	History of suicidality and alcohol craving trajectories during inpatient treatment for alcohol use disorder. Drug and Alcohol Dependence, 2020, 209, 107918.	3.2	5
36	Common Factors Underlying Diverse Responses in Alcohol Use Disorder. Psychiatric Research and Clinical Practice, 2021, 3, 76-87.	2.4	4

#	Article	IF	CITATIONS
37	Characteristics Associated With High-Intensity Binge Drinking in Alcohol Use Disorder. Frontiers in Psychology, 2021, 12, 750395.	2.1	3
38	Insula Sensitivity to Unfairness in Alcohol Use Disorder. Alcohol and Alcoholism, 2018, 53, 201-208.	1.6	2
39	Elevated transferrin saturation in individuals with alcohol use disorder: Association with HFE polymorphism and alcohol withdrawal severity. Addiction Biology, 2022, 27, e13144.	2.6	2
40	S205. "Super Bingers†Traits and Consumption Patterns Associated With High-Intensity Drinking. Biological Psychiatry, 2019, 85, S376-S377.	1.3	1
41	A Distinct Neurophenotype of Fearful Face Processing in Alcohol Use Disorder With and Without Comorbid Anxiety. Alcoholism: Clinical and Experimental Research, 2020, 44, 2212-2224.	2.4	1